Abstract：
Cisplatin-based combos have become first-line treatment regimens in standard of care because of their high overall survival improvement. Despite being the first-line therapy, due to its side effects, roughly half of all patients suffering from Metastatic urothelial cancer are ineligible for it. To address this issue, scientists have been developing highly specific antibody-drug conjugates to address this issue. For locally advanced or metastatic bladder cancer, a combination of Padcev (enfortumab vedotin-ejfv) with pembrolizumab (Keytruda) has been authorized by the FDA as a first-line treatment and has shown promising outcomes in patients with metastatic urothelial carcinoma who are ineligible for cisplatin-based combinations.
摘要：
基于顺铂的组合已成为标准护理的一线治疗方案，因为它们具有较高的总体生存率改善。尽管是一线治疗，由于它的副作用，大约一半患有转移性尿路上皮癌的患者不符合该疾病的治疗条件。为了解决这个问题，科学家们一直在开发高度特异性的抗体-药物结合物来解决这个问题。对于局部晚期或转移性膀胱癌，Padcev(enfortumabvedotin-ejfv)联合pembrolizumab(Keytruda)已被FDA批准作为一线治疗方案,并在不适合使用以顺铂为基础的联合治疗的转移性尿路上皮癌患者中显示出有希望的结局.
